T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$7.49B |
| 2 |
Micron Technology
MU
|
+$6.62B |
| 3 |
Lam Research
LRCX
|
+$3.45B |
| 4 |
Applied Materials
AMAT
|
+$3.03B |
| 5 |
Advanced Micro Devices
AMD
|
+$2.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$12.1B |
| 2 |
Apple
AAPL
|
+$11.6B |
| 3 |
Amazon
AMZN
|
+$3.54B |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$3.07B |
| 5 |
Keysight
KEYS
|
+$1.82B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.73% |
| 2 | Healthcare | 11.3% |
| 3 | Financials | 10.32% |
| 4 | Communication Services | 9.66% |
| 5 | Industrials | 9.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1001
Interparfums
IPAR
$3.78B
| $33.2M | ﹤0.01% |
296,771
+84,390
| +40% | +$7.96M |
|
1002
Edgewise Therapeutics
EWTX
$4.32B
| $33.2M | ﹤0.01% |
816,518
+747,091
| +1,076% | +$25.8M |
|
|
CSW
1003
CSW Industrials
CSW
$4.81B
| $33M | ﹤0.01% |
118,749
-22,365
| -16% | -$6.2M |
|
|
EROC
1004
ERock Inc
EROC
$572M
| $33M | ﹤0.01% |
+2,275,983
| New | +$36.2M |
|
1005
Church & Dwight Co
CHD
$22.7B
| $33M | ﹤0.01% |
340,348
+4,026
| +1% | +$385K |
|
|
RAPP
1006
Rapport Therapeutics
RAPP
$1.6B
| $32.8M | ﹤0.01% |
787,446
-79,010
| -9% | -$2.9M |
|
1007
Insulet
PODD
$9.23B
| $32.6M | ﹤0.01% |
214,349
-68,288
| -24% | -$11.4M |
|
1008
Landstar System
LSTR
$5.61B
| $32.6M | ﹤0.01% |
157,669
+100,660
| +177% | +$19.2M |
|
1009
Outfront Media
OUT
$4.92B
| $32.4M | ﹤0.01% |
988,038
+825,651
| +508% | +$25.6M |
|
1010
Hims & Hers Health
HIMS
$6.71B
| $32.3M | ﹤0.01% |
932,220
-485,124
| -34% | -$13M |
|
1011
Expeditors International
EXPD
$24.5B
| $31.5M | ﹤0.01% |
193,371
+4,941
| +3% | +$764K |
|
|
APGE
1012
DELISTED
Apogee Therapeutics
APGE
| $31.5M | ﹤0.01% |
237,210
-905,942
| -79% | -$81.6M |
|
|
MIAX
1013
Miami International Holdings
MIAX
$3.36B
| $31.4M | ﹤0.01% |
844,464
+685,278
| +430% | +$30.6M |
|
1014
Babcock & Wilcox
BW
$857M
| $31.4M | ﹤0.01% |
2,225,293
+371,660
| +20% | +$6.31M |
|
1015
Corebridge Financial
CRBG
$15.1B
| $31.4M | ﹤0.01% |
1,095,785
-4,580,230
| -81% | -$124M |
|
1016
nLIGHT
LASR
$2.28B
| $31.3M | ﹤0.01% |
449,531
+145,382
| +48% | +$10.1M |
|
1017
Principal Financial Group
PFG
$24.5B
| $31.2M | ﹤0.01% |
289,846
+5,894
| +2% | +$598K |
|
|
ZBIO
1018
Zenas BioPharma
ZBIO
$1.8B
| $31.1M | ﹤0.01% |
1,226,928
+869,662
| +243% | +$17.3M |
|
1019
T. Rowe Price US Equity Research ETF
TSPA
$4.55B
| $31M | ﹤0.01% |
651,985
+3,578
| +0.6% | +$164K |
|
1020
Synaptics
SYNA
$3.98B
| $31M | ﹤0.01% |
249,247
-272,812
| -52% | -$30.8M |
|
1021
Allison Transmission
ALSN
$9.39B
| $31M | ﹤0.01% |
274,521
-90,811
| -25% | -$11M |
|
1022
Roku
ROKU
$22.7B
| $30.8M | ﹤0.01% |
223,069
-400,219
| -64% | -$48.8M |
|
1023
Nutanix
NTNX
$18.6B
| $30.6M | ﹤0.01% |
600,139
+99,989
| +20% | +$4.52M |
|
1024
Gates Industrial Corp
GTES
$6.75B
| $30.5M | ﹤0.01% |
1,089,060
+525,905
| +93% | +$13.5M |
|
1025
Vishay Precision Group
VPG
$944M
| $30.4M | ﹤0.01% |
202,922
+175,239
| +633% | +$16.3M |
|
Similar funds
T. Rowe Price Associates's Q2 2026 Portfolio in Review
As of Q2 2026, T. Rowe Price Associates held 3,356 positions worth $999B, up 16% from $865B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q2 2026 filing shows 224 new, 2,237 increased, 645 reduced and 116 closed positions. Its largest new stake was SpaceX: 10,709,016 shares worth $1.83B. The largest sale was Microsoft, an estimated $12.1B.
By sector, the portfolio is most concentrated in Technology at 38% of assets, up from 34% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2026 buy was SpaceX: 10,709,016 shares worth $1.83B.
- T. Rowe Price Associates added most to Alphabet (Google) Class A in Q2 2026, an estimated $7.49B increase.
- T. Rowe Price Associates's biggest Q2 2026 reduction was Microsoft, cutting an estimated $12.1B.
- T. Rowe Price Associates fully exited Sibanye-Stillwater in Q2 2026, selling an estimated $40.4M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $999B portfolio in Q2 2026.
- T. Rowe Price Associates opened 224 new positions and closed 116 in Q2 2026.
- T. Rowe Price Associates's portfolio value rose 16% quarter-over-quarter to $999B.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.